{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:42:20Z","timestamp":1770550940584,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T00:00:00Z","timestamp":1566864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-1075-0","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T13:03:03Z","timestamp":1566910983000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between serum IgG level and clinical course in primary sclerosing cholangitis"],"prefix":"10.1186","volume":"19","author":[{"given":"Theresa","family":"Hippchen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"G\u00f6ppert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Nils","family":"Gotthardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Heinz","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Stremmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-9230","authenticated-orcid":false,"given":"Christian","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"1075_CR1","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH, Folseraas T, Thorburn D, Vesterhus M. Primary sclerosing cholangitis \u2013 a comprehensive review. J Hepatol. 2017;67:1298\u2013323.","journal-title":"J Hepatol"},{"key":"1075_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrgastro.2010.155","volume":"7","author":"F Mendes","year":"2010","unstructured":"Mendes F, Lindor KD. Primary sclerosing cholangitis: overview and update. Nat Rev Gastroenterol Hepatol. 2010;7:611\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1075_CR3","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1053\/j.gastro.2009.11.046","volume":"138","author":"TH Karlsen","year":"2010","unstructured":"Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010;138:1102\u201311.","journal-title":"Gastroenterology."},{"key":"1075_CR4","first-page":"1","volume":"0","author":"R Alberts","year":"2017","unstructured":"Alberts R, De Vries EMG, Goode EC, et al. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut. 2017;0:1\u20138.","journal-title":"Gut."},{"key":"1075_CR5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","volume":"66","author":"M Kummen","year":"2017","unstructured":"Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017;66:611\u20139.","journal-title":"Gut."},{"key":"1075_CR6","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/ng.2616","volume":"45","author":"JZ Liu","year":"2013","unstructured":"Liu JZ, Hov JR, Folseraas T, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet. 2013;45:670\u20135.","journal-title":"Nat Genet"},{"key":"1075_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/gut.24.1.38","volume":"24","author":"RW Chapman","year":"1983","unstructured":"Chapman RW, Varghese Z, Gaul R, et al. Association of primary sclerosing cholangitis with HLA-B8. Gut. 1983;24:38\u201341.","journal-title":"Gut."},{"key":"1075_CR8","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJM199006283222603","volume":"322","author":"EJ Prochazka","year":"1990","unstructured":"Prochazka EJ, Terasaki PI, Park MS, Goldstein LI, Busuttil RW. Association of Primary Sclerosing Cholangitis with HLA-DRw52a. N Engl J Med. 1990;322:1842\u20134.","journal-title":"N Engl J Med"},{"key":"1075_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ng.728","volume":"43","author":"E Melum","year":"2011","unstructured":"Melum E, Franke A, Schramm C, et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet. 2011;43:17\u20139.","journal-title":"Nat Genet"},{"key":"1075_CR10","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1111\/j.1572-0241.2000.03292.x","volume":"95","author":"S Saarinen","year":"2000","unstructured":"Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol. 2000;95:3195\u20139.","journal-title":"Am J Gastroenterol"},{"key":"1075_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/liv.12028","volume":"33","author":"C Rupp","year":"2013","unstructured":"Rupp C, Mummelthei A, Sauer P, et al. Non- IBD immunological diseases are a risk factor for reduced survival in PSC. Liver Int. 2013;33:86\u201393.","journal-title":"Liver Int"},{"key":"1075_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.bpg.2011.10.009","volume":"25","author":"MJ Pollheimer","year":"2011","unstructured":"Pollheimer MJ, Halilbasic E, Fickert P, Trauner M. Pathogenesis of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25:727\u201339.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"1075_CR13","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/hep.23584","volume":"51","author":"MP Manns","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u2013213.","journal-title":"Hepatology."},{"key":"1075_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.29204","volume":"66","author":"MR Deneau","year":"2017","unstructured":"Deneau MR, El-Matary W, Valentino PL, et al. The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration. Hepatology. 2017;66:518\u201327.","journal-title":"Hepatology."},{"key":"1075_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","volume":"54","author":"KM Boberg","year":"2011","unstructured":"Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374\u201385.","journal-title":"J Hepatol"},{"key":"1075_CR16","doi-asserted-by":"publisher","first-page":"e112877","DOI":"10.1371\/journal.pone.0112877","volume":"9","author":"LM Stinton","year":"2014","unstructured":"Stinton LM, Bentow C, Mahler M, et al. PR3-ANCA: a promising biomarker in primary Sclerosing cholangitis (PSC). PLoS One. 2014;9:e112877.","journal-title":"PLoS One"},{"key":"1075_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo P, Peter JB, Gershwin ME, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol. 2000;32:182\u20137.","journal-title":"J Hepatol"},{"key":"1075_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","volume":"66","author":"ST Jendrek","year":"2017","unstructured":"Jendrek ST, Gotthardt D, Nitzsche T, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66:137\u201344.","journal-title":"Gut."},{"issue":"10139","key":"1075_CR19","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"Jessica K Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, Jones DEJ, et al. Primary sclerosing cholangitis. Lancet. 2018;13. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(18)30300-3\n                    \n                   [Epub ahead of print].","journal-title":"The Lancet"},{"key":"1075_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","volume":"63","author":"EASL Clinical Practice Guidelines","year":"2015","unstructured":"EASL Clinical Practice Guidelines. Autoimmune hepatitis. J Hepatol. 2015;63:971\u20131004.","journal-title":"J Hepatol"},{"key":"1075_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/hep.22322","volume":"48","author":"EM Hennes","year":"2008","unstructured":"Hennes EM, Zeniya M, Czaja A, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48:169\u201376.","journal-title":"Hepatology."},{"key":"1075_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1665-2681(19)30869-5","volume":"13","author":"JH Tabibian","year":"2014","unstructured":"Tabibian JH, Enders F, Imam MH, et al. Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis. Ann Hepatol. 2014;13:384\u20139.","journal-title":"Ann Hepatol"},{"key":"1075_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/201834a0","volume":"201","author":"TB Tomasi Jun","year":"1964","unstructured":"Tomasi Jun TB, Tisdale WA. Serum gamma-globulins in acute and chronic liver diseases. Nature. 1964;201:834\u20135.","journal-title":"Nature."},{"key":"1075_CR24","first-page":"1","volume":"0","author":"C Rupp","year":"2017","unstructured":"Rupp C, R\u00f6ssler A, Zhou T, et al. Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. United European Gastroenterol J. 2017;0:1\u20138.","journal-title":"United European Gastroenterol J"},{"key":"1075_CR25","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1478-3231.2008.01726.x","volume":"28","author":"A Tanaka","year":"2008","unstructured":"Tanaka A, Takamori Y, Toda G, Ohnishi S, Takikawa H. Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis. Liver Int. 2008;28:983\u20139.","journal-title":"Liver Int"},{"key":"1075_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/00365520600787994","volume":"42","author":"A Bergquist","year":"2007","unstructured":"Bergquist A, Said K, Broom\u00e9 U, et al. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterology. 2007;42:88\u201393.","journal-title":"Scand J Gastroenterology"},{"key":"1075_CR27","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/MCG.0b013e318154af74","volume":"42","author":"S L\u00fcth","year":"2008","unstructured":"L\u00fcth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol. 2008;42:926\u201330.","journal-title":"J Clin Gastroenterol"},{"key":"1075_CR28","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/0016-5085(94)90610-6","volume":"106","author":"TA Knox","year":"1994","unstructured":"Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology. 1994;106:494\u20139.","journal-title":"Gastroenterology."},{"key":"1075_CR29","first-page":"511","volume":"91","author":"KD Lindor","year":"1996","unstructured":"Lindor KD, Jorgensen RA, Anderson ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol. 1996;91:511\u20135.","journal-title":"Am J Gastroenterol"},{"key":"1075_CR30","doi-asserted-by":"publisher","first-page":"e0140525","DOI":"10.1371\/journal.pone.0140525","volume":"10","author":"K Schulze","year":"2015","unstructured":"Schulze K, Weism\u00fcller TJ, Bubenheim M, et al. Criteria used in clinical practice to guide immunosuppressive treatment in patients with primary Sclerosing cholangitis. PLoS One. 2015;10:e0140525.","journal-title":"PLoS One"},{"issue":"9","key":"1075_CR31","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1111\/j.1572-0241.2006.00772.x","volume":"101","author":"FD Mendes","year":"2006","unstructured":"Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration in patients with primary Sclerosing cholangitis. Am J Gastroenterol. 2006;101(9):2070\u20135.","journal-title":"Am J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-1075-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-1075-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T23:14:26Z","timestamp":1598397266000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-1075-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,27]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1075"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-1075-0","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,27]]},"assertion":[{"value":"2 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent for clinical and laboratory data acquisition and analysis was obtained from each patient at entry into the study. Data acquisition and evaluation was approved by the local ethics committee of Heidelberg University (S-043\/2011) and conformed to the ethical guidelines of the Declaration of Helsinki, as reflected in an a priori approval by the institution\u2019s human research review committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}